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Abstract : Cough is one of the most common symptoms seen in clinical practice, however the differential di-
agnosis is often difficult. The utility of fractional exhaled nitric oxide (FeNO) measurement in the differential 
diagnosis of the etiology of cough has been reported. NIOX VERO® (NOV) is a new hand-held device that will 
replace NIOX MINO®, but its diagnostic utility has not been fully elucidated in clinical practice. In this study, 
the performance of NOV for FeNO measurements was determined. We retrospectively analyzed 243 consecutive 
patients complaining cough. Among 243 patients, final diagnosis was cough variant asthma (CVA) in 74 (30.5%), 
bronchial asthma (BA) in 48 (19.8%), post-infectious cough (PIC) in 52 (21.4%), atopic chough (AC) in 24 (9.9%), 
gastroesophageal reflux disease (GERD) in 10 (4.1%), and Others in 35 (14.4%). FeNO values were significantly 
higher in CVA and BA as compared to PIC, AC, GERD, and Others. In the multivariate analysis, only FeNO value 
was identified as independent factors to discriminate CVA and non-CVA other than BA. These findings indicated 
that FeNO measured by using NOV could be used as a diagnostic marker of intractable cough, especially for the 
differential diagnosis of CVA from non-CVA. J. Med. Invest. 67 : 265-270, August, 2020
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INTRODUCTION
 
Cough is one of the most common symptoms for which pa-
tients seek medical attention (1), however proper diagnosis of 
its etiology is often difficult (2). Morice et al. report that the most 
common diagnoses in patients with chronic cough are cough 
variant asthma (CVA), sinobronchial syndrome (SBS), and gas-
troesophageal reflux disease (GERD), followed by eosinophilic 
bronchitis (EB) without bronchial asthma (BA), chronic bron-
chitis, post-infectious cough (PIC), and angiotensin-converting 
enzyme inhibitor-induced cough (3). In Japan, the prevalence of 
CVA, atopic cough (AC), and SBS is reported to be high, whereas 
that of GERD as a cause of chronic cough tends to be low (4). For 
the adequate treatment and symptom relief of patients, the ac-
curate diagnosis of the etiology of cough is an important clinical 
concern.
The tests required for diagnosing CVA and EB, such as 
bronchial challenge tests and induced sputum analyses, are 
technically demanding and require specialized instruments and 
personnel (5, 6). Thus, their use is restricted to specialist centers. 
Fractional exhaled nitric oxide (FeNO) measurement is consid-
ered a useful surrogate marker of Th2-driven airway inflamma-
tion (7). FeNO values correlate with sputum eosinophil count 
(8), and higher FeNO values have been reported in asthmatic 
patients compared with non-asthmatic subjects (9). The great 
advantage of measuring FeNO values is that it only requires a 
simple, rapid, and noninvasive test (10), potentially enabling the 
test to be widely used in clinical practice. Although the utility of 
FeNO measurements in the differential diagnosis of prolonged 
or chronic cough has been reported (11), its diagnostic utility can 
vary with the target population, and no specific recommendation 
has been made for patients with chronic cough (10).
In Japan, three devices are used for the measurement of FeNO 
and are covered by insurance, namely, NIOX MINO®, NIOX 
VERO® (NOV) and NObreath®. NOV is a new device that will 
replace NIOX MINO®, and the use of NOV was previously limit-
ed owing to its high cost. However, after being approved for cov-
erage by the national health insurance in March 2015, the use of 
NOV has increased. Because NOV has not been used for many 
years in clinical practice, and few studies have been performed to 
measure FeNO values obtained using NOV, its diagnostic utility 
has not been fully elucidated.
In this study, we investigated the clinical utility of FeNO mea-
surement obtained using NOV for the evaluation and differential 
diagnosis of allergic airway inflammatory disorders in patients 
with intractable cough. 
MATERIALS AND METHODS
Patients
We retrospectively analyzed 243 consecutive patients who 
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visited the Department of Respiratory Medicine, Shikoku Cen-
tral Hospital of the Mutual aid Association of Public School 
teachers from April 2018 through June 2019, with a chief com-
plaint of cough. Inclusion criteria were as follows : 1) age ≥ 15 
years, 2) being able to undergo FeNO measurement, and 3) 
providing informed consent to participate in the study. Patients 
were excluded if they : 1) were in lactation and breastfeeding, 2) 
were in a pregnancy, 3) had significant psychological problems, 
4) had abnormal chest radiograph findings that may explain the 
cough, or 5) had taken systemic corticosteroids, antihistamines, 
anti-leukotriene agents, medications for cough within the previ-
ous two weeks. Patients with respiratory symptoms other than 
cough, such as fever, sputum, shortness of breath, wheezes and 
stridor, were included. For the comparison of FeNO values, age-
matched 30 healthy volunteers were also included.
The study was conducted in accordance with the Declaration 
of Helsinki and the study protocol was approved by the Institu-
tional Review Board of our institution (approval number ; 2019-
1-1, approval date ; 2019 / 5 / 16). The statement on consent to 
participate in this study was obtained from patients by the 
disclosure of information for participation. 
Study Design
Questionnaires concerning past and/or present illness, occu-
pation, cough duration, other respiratory symptoms and current 
smoking status including the number of cigarettes smoked 
per day and smoking duration were assessed. The smoking 
index was defined as multiplying the numbers of cigarette pack 
smoked per day by smoking years (pack-years), to estimate how 
the patients were exposed to smoking.
All patients underwent FeNO measurement. FeNO values 
were measured by NOV electrochemical analyzer (Aerocrine 
AB, Solna, Sweden) at a flow rate of 50 mL / seconds, according 
to the American Thoracic Society / European Respiratory Society 
recommendations (12) and were expressed as parts per billion 
(ppb). The patients were asked to empty their lungs and then 
inhale deeply through the filter to total lung capacity. Next, they 
exhaled slowly through the filter and regulated their exhaled 
flow rate through assistance by an animation display. The exha-
lation time was adjusted to 10 seconds for all patients. Measure-
ments were repeated until one acceptable value was obtained, 
as judged by the machine. Blood tests included peripheral blood 
white blood cell count, peripheral blood eosinophil count, serum 
non-specific immunoglobulin E (IgE), and serum antigen-specif-
ic IgE as appropriate. A chest radiograph was also evaluated in 
order to exclude other undiagnosed diseases.
The diagnoses of the etiology of cough were made as follows. 
BA was diagnosed when patients had cough as the predominant 
symptoms while together with wheezes and/or dyspnea, and 
either positive airway reversibility or reversible airflow obstruc-
tion (13). A diagnosis of CVA was based on the sole complaint 
of cough, not accompanied by wheezes or dyspnea, which was 
relieved by β2-agonists, and positive airway reversibility or re-
versible airflow obstruction (4). AC was diagnosed based on the 
presence of atopic status and response of coughing to histamine 
H1 receptor antagonist, but not to inhaled β2-agonist (4, 14). PIC 
was diagnosed when cough was preceded by an acute respiratory 
tract infection that was not complicated by pneumonia and even-
tually resolved spontaneously (4). SBS was diagnosed based on 
findings of chronic sinusitis on sinus imaging and improvement 
of cough and symptoms related to chronic sinusitis with macro-
lide antibiotics (4, 15). GERD-related cough was suspected by the 
presence of 1) classic reflux symptoms of heartburn, indigestion, 
chest discomfort, throat clearing, dysphonia, dysphagia, and 
belching and/or 2) typical characteristics of cough that is trig-
gered by phonation, rising, lying, eating, and intake of certain 
food. A diagnosis was confirmed when cough was relieved by 
proton pump inhibitors with or without gastrointestinal proki-
netic agents (16).
Statistical analysis 
The significant differences between populations were eval-
uated with Fisher’s exact test in categorized variables and 
Student’s t-test in continuous variables. Data are described as 
the means ± standard deviations (SDs), unless otherwise stated. 
Correlations between FeNO values and blood eosinophil counts 
and total serum IgE titers were analyzed by Spearman’s rank 
correlation test. Intended for 195 patients whose final diagnoses 
were other than BA, the univariate analysis was done to evalu-
ate the patient characteristics that were significantly associated 
with the diagnosis of CVA ; specifically, these factors were age, 
gender, body mass index (BMI), smoking status, smoking index, 
cough duration, past and / or present illness, blood eosinophil 
count, total serum IgE titer, and FeNO value. Variables that had 
a P-value of < 0.05 in the univariate analysis were included in 
the multivariate logistic regression analysis to evaluate which 
one predict the diagnosis of CVA. The cut-off value for distin-
guishing CVA from non-CVA except for BA was determined by 
receiver operating characteristic (ROC) curve analysis. Two-
tailed P-values of < 0.05 were considered significant. All analy-
ses were performed using EZR (Saitama Medical Center, Jichi 
Medical University, Saitama, Japan), which is a graphical user 
interface for R (The R Foundation for Statistical Computing, 
Vienna, Austria) (17).
RESULTS
From April 2018 through June 2019, 243 consecutive patients 
with a chief complaint of cough were enrolled in this study. Their 
clinical characteristics are listed in Table 1. The mean age was 
52.6 years, with a range of 16-89. Eighty-seven patients (35.8%) 
were male, and 156 (64.2%) were female. The mean cough dura-
tion was 8.1 weeks (range ; 0.14-104 weeks), and the mean BMI 
was 23.2 ± 3.9 kg / m2 (range ; 14.8-37.1 kg / m2). Seventy-eight 
patients (32.1%) had smoking experience (current or former), and 
the mean smoking index was 8.0 ± 16.9 pack-year (range ; 0.0-
87.5 pack-year). Seventy-five patients (30.0%) had the past his-
tory of BA. The past and / or present illness of allergic diseases 
except for BA, SBS and GERD were observed in 112 (46.1%), 51 
(21.0%), and 45 (18.5%) patients, respectively.
Among 243 patients, final diagnosis of the etiology of cough 
was CVA in 74 (30.5%), BA in 48 (19.8%), PIC in 52 (21.4%), AC 
in 24 (9.9%), GERD-related cough in 10 (4.1%), and Others in 
35 (14.4%) (Table 2). BA and CVA constituted more than a half 
(50.2%) of the whole population. Comparison of patients with 
cough according to etiology is shown in Table 3. Compared with 
CVA group, BA group had significantly lower BMI and higher 
smoking experience, PIC group had significantly lower blood 
eosinophil count, and AC group were significantly younger. The 
cough duration in PIC group was significantly shorter than 
other etiologies. The earlier admission in this group seemed to be 
mainly attributed to their more serious symptoms such as fever, 
sore throat, chillness, other than cough.
FeNO values were significantly higher in patients with CVA 
(40.1 ± 26.0 ppb) and in those with BA (40.4 ± 33.3 ppb) than in 
PIC (15.6 ± 7.7 ppb), AC (17.9 ± 9.9 ppb), GERD (14.9 ± 4.7 ppb), 
and Others (17.1 ± 9.4 ppb ; P < 0.05 each). There was no signif-
icant difference of FeNO values in patients with CVA and BA 
(Figure 1). FeNO values in 30 healthy volunteers (16.6 ± 6.5 ppb) 
were also significantly lower compared with CVA and BA, while 
no difference was observed from those in PIC, AC, GERD, and 
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Others (data not shown). FeNO values significantly correlated 
with blood eosinophil counts (r = 0.35, P < 0.01), and total serum 
IgE titers (r = 0.17, P = 0.03) (data not shown).
The proper diagnosis of the etiology of cough is often trouble-
some (2). The diagnosis of BA is considered to be made easier 
than other etiologies of cough due to the existence of wheezes in 
chest auscultation, but the differential diagnosis of CVA from 
non-CVA other than BA is extremely difficult due to few positive 
findings in physical examination. To facilitate the differential di-
agnosis of the etiology of cough and to identify the factors which 
predict the diagnosis of CVA, we next focused on 195 patients 
whose final diagnoses were other than BA. In the univariate 
analysis, which compared the patient characteristics that were 
significantly associated with the diagnosis of CVA, the factors 
that were identified to have significant effects (P < 0.05) were 
smoking status, past history of BA, blood eosinophil count, total 
serum IgE titer, and FeNO value (Table 4). These five variables 
were included in the following multivariate logistic regression 
analysis to evaluate which one predict the diagnosis of CVA. In 
the multivariate analysis, only FeNO value was identified as 
independent factors associated with the diagnosis of CVA (Table 
5).
Finally, we exploratory sought to determine the best cut-off 
point of FeNO to discriminate CVA and non-CVA other than 
BA. The overall diagnostic utility of FeNO value to distinguish 
these two groups was examined by ROC curve analysis, which 
revealed 23 ppb, with an area under the ROC curve of 0.87 (95% 
confidence interval (CI) ; 0.82-0.93), as the optimal cut-off value 









BMI, kg / m2 23.2 ± 3.9 (14.8-37.1)*
Smoking status, N (%)
Current 24 (  9.9%)
Former 54 (22.2%)
Never 165 (67.9%)
Smoking index, pack-year 8.0 ± 16.9 (0.0-87.5)*
Cough duration, weeks 8.1 ± 14.8 (0.14-104)*





Data are described as the means ± SDs.
*Numbers in parentheses indicated ranges of each variable.
BMI, body mass index ; BA, bronchial asthma ; AD, allergic dis-
eases ; SBS, sinobronchial syndrome ; GERD, gastroesophageal 
reflux disease
Table 2.　Etiology of cough in our study population.
Diagnosis Number (%)
Cough variant asthma 74 (30.5)
Bronchial asthma 48 (19.8)
Post-infectious cough 52 (21.4)
Atopic cough 24 (  9.9)
Gastroesophageal reflux disease 10 (  4.1)
Others
Sinobronchial syndrome 9 (  3.7)
Chronic obstructive pulmonary disease 8 (  3.3)
Interstitial lung diseases 5 (  2.1)
Chronic aspiration 4 (  1.6)
Drug-induced cough 2 (  0.8)
Chronic heart failure 2 (  0.8)
Not otherwise specified 5  ( 2.1)
Table 3.　Comparison of patients with cough according to etiology.
Variables CVA BA PIC AC GERD Others
Number 74 48 52 24 10 35
Age (years) 51.8 ± 17.2 53.3 ± 19.7 47.4 ± 18.6 40.0 ± 16.6* 49.1 ± 17.1 71.0 ± 11.6*
Gender (male / female) 28 / 46 20 / 28 13 / 39 6 / 18 5 / 5 15 / 20
BMI (kg / m2) 23.8 ± 3.9 21.6 ± 3.5* 23.9 ± 3.5 22.8 ± 4.8 22.7 ± 2.4 23.8 ± 3.9
Smoking status (current / former / never) 11 / 12 / 51 8 / 18 / 22* 1 / 8 / 43 0 / 4 / 20 0 / 2 / 8 4 / 10 / 21
Smoking index (pack-year) 5.8 ± 12.6 11.1 ± 17.3 3.2 ± 9.0 2.3 ± 6.8 8.2 ± 17.6 19.4 ± 28.9*
Cough duration (weeks) 8.0 ± 15.9 10.7 ± 20.7 2.6 ± 2.0* 6.7 ± 10.7 8.5 ± 7.9 14.4 ± 15.5
Blood eosinophil ( / μL) 305 ± 231 467 ± 670 187 ± 175* 234 ± 201 190 ± 103 195 ± 177*
Total serum IgE (IU / mL) 502 ± 1227 942 ± 2288 202 ± 505 254 ± 322 99 ± 127 216 ± 475
Data are described as the means ± SDs. *P < 0.05 compared with CVA.
CVA, cough variant asthma ; BA, bronchial asthma ; PIC, post-infectious cough ; AC, atopic cough ; GERD, gastroesophageal reflux dis-
ease ; BMI, body mass index ; IgE, immunoglobulin E ; IU, international unit ; SD, standard deviation
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Figure 1.　Comparison of FeNO values in each group of patients with a chief complaint of cough. FeNO values 
were significantly higher in patients with CVA and BA than in those with PIC, AC, GERD, and Others (P < 0.05 
each, by Student’s t-test). There was no significant difference of FeNO values in patients with CVA and BA. Data 
are shown as the means ± standard errors. *P < 0.05 compared with the patients with CVA and BA.
Table 4.　Univariate analysis of factors affecting the diagnosis of CVA and non-CVA in patients with cough.
Variables CVA non-CVA P-value
Number 74 121
Age (year) 54.0 ± 18.6 53.0 ± 18.8 0.733
Gender (male / female) 28 / 46 39 / 82 0.441
BMI (kg / m2) 24.0 ± 4.0 23.5 ± 3.8 0.437
Smoking status (current / former / never) 11 / 12 / 51 5 / 21 / 92 0.040 
Smoking index (pack-year) 5.8 ± 12.6 8.1 ± 18.9 0.355
Cough duration (weeks) 8.0 ± 15.9 7.2 ± 10.9 0.666
History of BA (N [%]) 22 [29.7] 12 [9.9] < 0.001
History of AD (N [%]) 33 [45.0] 54 [44.6] 1.000 
History of SBS (N [%]) 16 [21.6] 22 [18.2] 0.580 
History of GERD (N [%]) 17 [23.0] 21 [17.4] 0.356
Blood eosinophil ( / μL) 305 ± 231 199 ± 176 < 0.001
Total serum IgE (IU / mL) 502 ± 1227 213 ± 451 0.048
FeNO (ppb) 40.1 ± 26.0 16.1 ± 7.8 < 0.001
Data are described as the means ± SDs. 
CVA, cough variant asthma; BMI, body mass index ; BA, bronchial asthma ; AD, allergic diseases ; SBS, 
sinobronchial syndrome ; GERD, gastroesophageal reflux disease ; IgE, immunoglobulin E ; IU, interna-
tional unit ; FeNO, fractional exhaled nitric oxide ; ppb, parts per billion ; SD, standard deviation
Table 5.　Multivariate logistic regression analysis for prediction of 
CVA diagnosis in patients with cough.
Parameter Odds ratio (95% CI) P-value
FeNO (ppb) 0.868 (0.824-0.914) < 0.001
History of BA 0.318 (0.086-1.170) 0.085
Smoking status 2.600 (0.747-9.050) 0.133
Blood eosinophil ( / μL) 0.999 (0.997-1.000) 0.576
Total serum IgE (IU / mL) 1.000 (0.999-1.000) 0.966
CVA, cough variant asthma ; CI, confidence interval ; FeNO, frac-
tional exhaled nitric oxide ; BA, bronchial asthma ; IgE, immuno-
globulin E
Figure 2.　The ROC curve analysis for distinguishing CVA from 
non-CVA other than BA as the etiology of cough. The overall optimal 
cut-off value was 23 ppb, with an area under the ROC curve of 0.87 
(95% CI ; 0.82-0.93). This resulted in a sensitivity and specificity of 
85.1% and 81.1%, respectively.
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DISCUSSION
Since a new hand-held device for FeNO measurement, NOV, 
has not been used for many years in clinical practice, and few 
studies have been performed to measure FeNO values obtained 
using NOV, its diagnostic utility has not been fully elucidated. In 
this study, we sought to investigate the performance of NOV for 
the evaluation and differential diagnosis of the etiology of cough. 
FeNO values were significantly higher in patients with CVA and 
BA as compared to those with PIC, AC, GERD and Others, and 
significantly correlated with blood eosinophil counts and total 
serum IgE titers. Moreover, only FeNO value was identified as 
independent factors to discriminate CVA and non-CVA in the 
multivariate analysis. These findings indicated that FeNO val-
ues measured by using NOV was a relevant diagnostic tool for 
the patients suffering from intractable cough.
It is well established that FeNO values are higher in patients 
with CVA and BA than in healthy controls (18). Kowal et al. re-
ported the cut-off value to differentiate a chronic cough with and 
without BA was 40 ppb (sensitivity, 0.88 ; specificity, 0.83) (19). 
Matsunaga et al. demonstrated that the cut-off value of FeNO 
22 ppb measured by using NIOX MINO® was associated with 
the highest combination of sensitivity (90.8%) and specificity 
(83.9%) to differentiate asthmatic patients and control subjects 
(20), which was comparable with our results obtained by using 
NOV. The present study indicated a cut-off value of 23 ppb (sen-
sitivity, 0.85 ; specificity, 0.81) for differentiation between CVA 
and non-CVA other than BA. The discrepancies of cut-off levels 
among these studies may be attributed to different methods of 
selection of cases (category of BA and CVA) and control group 
(CVA, non-CVA or healthy control) and the varying patients’ 
characteristics. Lúdvíksdóttir et al. reported that atopic patients 
with BA had a significantly higher mean exhaled NO than 
non-atopic subjects with BA (21). In this study, FeNO values had 
a significantly positive correlation with blood eosinophil counts 
and total serum IgE titers. These data support that FeNO is a 
useful marker to monitor the eosinophilic inflammation in pa-
tients with CVA and BA patients.
The difference in FeNO values between BA and CVA seems 
controversial. Although our study demonstrated these signif-
icant differences, other reports reported otherwise (22). Since 
a degree of mucosal and bronchoalveolar eosinophilia between 
BA and CVA are similar (23), there is a possibility that varying 
influences of confounding factors, such as atopic status (24), and 
disease severity may have affected the results. Several factors 
may affect the validity of FeNO measurements. In patients 
with BA, Matsunaga et al. proposed that FeNO values should be 
evaluated while considering the influence of allergic rhinitis and 
smoking (20). Previous studies also revealed that atopic status 
and diagnosis were independent determinants of FeNO values in 
patients with prolonged and chronic cough and that atopy itself 
was responsible for elevated FeNO values even among subjects 
without BA or lower airway symptoms (25), which may lead to 
misdiagnosis of asthma. Therefore, taking these factors into 
account seemed to be inevitable when evaluating FeNO values 
in prolonged and chronic cough.
There are now several manufacturers of FeNO analyzers. 
Consequently, reports of FeNO measurement have often used 
different equipment (26). Therefore, FeNO values were reported 
to be significantly different among the equipment used, while 
the procedure of FeNO measurement has been standardized. 
Inoue et al. demonstrated that NIOX devices (e.g., NIOX®, NIOX 
MINO® and NOV) showed higher FeNO values in the low-FeNO 
population, whereas NObreath® showed higher values in the 
high-FeNO population (27), indicating the effectiveness of the 
device appeared to be controlled by the FeNO value in the target 
population. On the contrary, FeNO values measured by differ-
ent devices were shown to have good correlation and clinically 
acceptable agreement between NIOX® and NIOX MINO® (28), 
NIOX MINO® and NOV (29), NObreath® and NOV (27), respec-
tively. These findings indicated that each device was able to give 
clinical guidance with similar accuracy.
Several major limitations need to be considered in interpreting 
our findings. First, this is a retrospective study with somewhat 
small number of patients. Thus, it is difficult to draw definite 
conclusions about the utility of FeNO measurement obtained 
using NOV for diagnosing the etiology of cough in daily practice. 
Second, as this study was performed in only one institution, the 
results should not be universalized to the general population. 
Third, we did now specify cough duration in eligibility criteria. 
Thus, not only patients with prolonged and chronic cough but 
those with acute phase of cough were also included in this study. 
Forth, current diagnostic criteria for CVA might not be precise 
because 1) they are often based on positive airway reversibility 
and might not preclude post-viral cough and 2) are premised on 
good clinical response to asthma therapy and might not encom-
pass refractory asthma. The present findings on CVA need to be 
interpreted cautiously. Further large-scale studies would be re-
quired to show the more clinically significant data in the future.
In conclusion, we investigated the clinical utility of FeNO 
measurement obtained using NOV for diagnosing the etiology 
of cough in this study. FeNO values were significantly higher in 
patients with CVA and BA as compared to those with PIC, AC, 
GERD and Others, and significantly correlated with blood eo-
sinophil counts and total serum IgE titers. Moreover, only FeNO 
value was identified as independent factors to discriminate CVA 
and non-CVA in the multivariate analysis. These findings indi-
cated that FeNO values measured by using NOV could be used 
as a diagnostic marker of cough, especially for the differential 
diagnosis of CVA from non-CVA.
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